214 related articles for article (PubMed ID: 27664328)
1. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
2. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
3. Organ Biodistribution of Radiolabelled γδ T Cells Following Liposomal Alendronate Administration in Different Mouse Tumour Models.
Wang JT; Hodgins NO; Al-Jamal WT; Maher J; Sosabowski JK; Al-Jamal KT
Nanotheranostics; 2020; 4(2):71-82. PubMed ID: 32190534
[TBL] [Abstract][Full Text] [Related]
4. Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.
Hodgins NO; Al-Jamal WT; Wang JT; Klippstein R; Costa PM; Sosabowski JK; Marshall JF; Maher J; Al-Jamal KT
J Control Release; 2017 Jun; 256():141-152. PubMed ID: 28432037
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
6. In Vivo PET Tracking of
Man F; Lim L; Volpe A; Gabizon A; Shmeeda H; Draper B; Parente-Pereira AC; Maher J; Blower PJ; Fruhwirth GO; T M de Rosales R
Mol Ther; 2019 Jan; 27(1):219-229. PubMed ID: 30429045
[TBL] [Abstract][Full Text] [Related]
7. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
[TBL] [Abstract][Full Text] [Related]
8. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
13. Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth.
Gutman D; Epstein-Barash H; Tsuriel M; Golomb G
Adv Exp Med Biol; 2012; 733():165-79. PubMed ID: 22101722
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
16. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
17. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
18. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
Wang S; Li H; Ye C; Lin P; Li B; Zhang W; Sun L; Wang Z; Xue D; Teng W; Zhou X; Lin N; Ye Z
Front Immunol; 2018; 9():377. PubMed ID: 29535738
[TBL] [Abstract][Full Text] [Related]
19. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
20. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
Kabelitz D; Wesch D; Pitters E; Zöller M
J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
